446 related articles for article (PubMed ID: 8567774)
21. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
22. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception.
Runic R; Schatz F; Krey L; Demopoulos R; Thung S; Wan L; Lockwood CJ
J Clin Endocrinol Metab; 1997 Jun; 82(6):1983-8. PubMed ID: 9177417
[TBL] [Abstract][Full Text] [Related]
23. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
[TBL] [Abstract][Full Text] [Related]
24. Menstrual bleeding patterns in Norplant-2 implant users.
Biswas A; Leong WP; Ratnam SS; Viegas OA
Contraception; 1996 Aug; 54(2):91-5. PubMed ID: 8842585
[TBL] [Abstract][Full Text] [Related]
25. Progesterone receptor in Norplant endometrium.
Lau TM; Witjaksono J; Rogers PA
Hum Reprod; 1996 Oct; 11 Suppl 2():90-4. PubMed ID: 8982750
[TBL] [Abstract][Full Text] [Related]
26. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use.
Kaewrudee S; Taneepanichskul S; Jaisamraun U; Reinprayoon D
Contraception; 1999 Jul; 60(1):25-30. PubMed ID: 10549449
[TBL] [Abstract][Full Text] [Related]
27. A review of the endometrial changes in Norplant users.
Wan LS
Ann N Y Acad Sci; 1997 Sep; 828():108-10. PubMed ID: 9329828
[TBL] [Abstract][Full Text] [Related]
28. Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant users.
Marbaix E; Vekemans M; Galant C; Rigot V; Lemoine P; Dubois D; Picquet C; Henriet P; Twagirayezu P; Sufi S; Eeckhout Y; Courtoy PJ
Hum Reprod; 2000 Aug; 15 Suppl 3():120-34. PubMed ID: 11041228
[TBL] [Abstract][Full Text] [Related]
29. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
30. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
[TBL] [Abstract][Full Text] [Related]
31. A five-year clinical evaluation of Norplant contraceptive subdermal implants in Bangladeshi acceptors.
Akhter H; Dunson TR; Amatya RN; Begum K; Chowdhury T; Dighe N; Krueger SL; Rahman S
Contraception; 1993 Jun; 47(6):569-82. PubMed ID: 8334891
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of Norplant implants among Thai women in Bangkok.
Chompootaweep S; Kochagarn E; Sirisumpan S; Tang-usaha J; Theppitaksak B; Dusitsin N
Contraception; 1996 Jan; 53(1):33-6. PubMed ID: 8631187
[TBL] [Abstract][Full Text] [Related]
33. Management of irregular uterine bleeding and spotting associated with Norplant.
Archer DF; Philput CA; Weber ME
Hum Reprod; 1996 Oct; 11 Suppl 2():24-30. PubMed ID: 8982742
[TBL] [Abstract][Full Text] [Related]
34. Immediate postpartum insertion of the norplant contraceptive device.
Molland JR; Morehead DB; Baldwin DM; Castracane VD; Lasley B; Bergquist CA
Fertil Steril; 1996 Jul; 66(1):43-8. PubMed ID: 8752609
[TBL] [Abstract][Full Text] [Related]
35. Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus.
Dunson TR; Blumenthal PD; Alvarez F; Brache V; Cochon L; Dalberth B; Glover L; Remsburg R; Vu K; Katz D
Fertil Steril; 1998 Feb; 69(2):258-66. PubMed ID: 9496339
[TBL] [Abstract][Full Text] [Related]
36. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
Alvarez F; Brache V; Faundes A; Tejada AS; Thevenin F
Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
[TBL] [Abstract][Full Text] [Related]
37. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
[TBL] [Abstract][Full Text] [Related]
38. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
[TBL] [Abstract][Full Text] [Related]
39. Benefits of vitamin E supplementation to Norplant users--in vitro and in vivo studies.
Subakir SB; Setiadi E; Affandi B; Pringgoutomo S; Freisleben HJ
Toxicology; 2000 Aug; 148(2-3):173-8. PubMed ID: 10962136
[TBL] [Abstract][Full Text] [Related]
40. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
